MET · Q4 2025 Earnings

Narrative arc: Q2 cautious carve-out → Q3 narrative repair → Q4 conviction with detailed segment guide.

Two quarters ago management was openly carving out the quarter as not demonstrating "full earnings power," with VII forecasting difficulty framed as structural. Last quarter the print delivered a clean offset and management moved from defense to "well ahead of schedule." This quarter management explicitly closes the arc: "One year into New Frontier, it is clear we have the right strategy at the right time, focused on the right growth opportunities, and measuring ourselves against the right metrics." That phrasing — "it is clear" — is the most prescriptive language MetLife has used about its own strategy in any of the last three quarters, and it sits behind the willingness to issue segment-level 2026 earnings bands rather than qualitative direction.

Q2 framed reinsurance and Chariot Re as opportunistic capital relief; Q3 elevated Chariot Re to executed-platform status with a first $10B transaction. This quarter management goes further and rebases the RIS disclosure framework around it: "RAS segment earnings will be driven by retained liability exposures net of reinsurance," with enhanced QFS statistical pages reflecting reinsurance impact. The shift signals that reinsurance is no longer a balance-sheet tool layered on top of organic earnings — it is the disclosure spine for how RIS will be modeled going forward. That has implications for how analysts compare 2026 RIS earnings to the 2025 base.

The expense ratio language has hardened in a way that requires careful reading. In Q3 management said year-end 2025 would come in "well below 12.1%." This quarter the FY2026 target is set at exactly 12.1%, with the explanation that Pinebridge adds 50bps and the 2029 target of 11.3% is maintained: "we intend to maintain our 2029 target of 11.3% direct expense ratio despite higher expense ratios from asset management growth." The 2025 outperformance is being absorbed by the M&A drag rather than dropped to the long-term floor. Whether that 50bps recaptures in 2027–2028 is now the central margin question.

Two new disclosure framings deserve flagging together: VII anchored explicitly at ~$1.6B pre-tax for 2026, and MIM established as a standalone segment with three-year forward targets. The VII anchor is the answer to Q2's forecasting-credibility issue — management is now committing to a number rather than warning of forecasting difficulty. The MIM standalone disclosure is the answer to "what is Pinebridge actually worth in the P&L" and provides the multi-year arc (~$240–280M in 2026 → +15–20% annually in 2027–2028 → ~32% margin by 2028) needed to underwrite the acquisition.

The risks management surfaced are concentrated and named: Q4 disability experience trailed expectations by slightly over one point in the non-medical health ratio (drove the target band shift), Mexico VAT impact still flagged for first-half 2026, real estate fund underperformance versus targets, and rising long-term rates impacting derivative valuations. The vs-typical posture is more confident and more prescriptive than MetLife's usual cautionary positioning — the cost is that the segment-level guide stack creates many more specific lines for the market to hold management to in 2026.